Physician profile
Daniel A Ermann
NPI 1386160596
$74,259.35
in general payments reported to CMS, 2019-2025
19 companies · $52K in 2025
The $52K reported for 2025 was more than what 94% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $277 · 2023: $559 · 2024: $21K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $28K · Travel and Lodging: $4,624 · Food and Beverage: $3,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,485.00 |
| Consulting Fee | $28,065.00 |
| Travel and Lodging | $4,624.14 |
| Food and Beverage | $3,682.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $42,591.21 | 2023-2025 | Calquence |
| Beone Medicines USA, INC. | $12,654.20 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $9,464.18 | 2024-2025 | |
| Incyte Corporation | $6,012.52 | 2023-2025 | Monjuvi, Jakafi, Monjuvi |
| Beigene USA, INC. | $1,988.81 | 2024 | Brukinsa |
| Abbvie INC. | $262.45 | 2023-2024 | |
| Genentech USA, INC. | $236.62 | 2023-2024 | Columvi, Polivy, Lunsumio |
| Genentech, INC. | $177.45 | 2021 | |
| Aveo Pharmaceuticals, INC. | $140.00 | 2024 | |
| Genmab U.S., INC. | $126.86 | 2025 | Epkinly |
| Celgene Corporation | $124.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $123.12 | 2024 | |
| Pfizer INC. | $108.42 | 2025 | |
| Seagen INC. | $99.97 | 2021 | |
| F. Hoffmann-La Roche Ag | $75.00 | 2025 | Actemra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $38.83 | 2023 | |
| Novartis Pharmaceuticals Corporation | $34.72 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.